Inhibitors of cholesteryl ester transfer protein--a new approach to coronary artery disease.

abstract：BACKGROUND:In the past years the bone seeking radiopharmaceutical samarium lexidronam ((153)Sm-EDTMP) has been increasingly used alone or in conjunction with chemotherapy and/or bisphosphonates for the treatment of painful bone metastasis. OBJECTIVE:Its use has been explored in different solid tumours. In this report ...

journal_title：Expert opinion on investigational drugs

authors： Abruzzese E,Iuliano F,Trawinska MM,Di Maio M

更新日期：2008-09-01 00:00:00

abstract：INTRODUCTION:Fibroblast growth factor receptors (FGFR 1-4) are a highly conserved family of receptor tyrosine kinases, involved in several physiological processes. Genetic aberrations of FGFRs and their ligands, fibroblast growth factors (FGFs) are involved in several pathological processes including cancer. The FGF-FG...

journal_title：Expert opinion on investigational drugs

authors： Chandana SR,Babiker HM,Mahadevan D

更新日期：2020-12-01 00:00:00

abstract：BACKGROUND:Age-related macular degeneration is the leading cause of blindness among elderly individuals in industrialized countries. New drugs and advanced concepts for the treatment of dry AMD (dAMD) are needed. A new approach is the application of intravenous infusions of prostaglandin E1. OBJECTIVE:The aim of this ...

journal_title：Expert opinion on investigational drugs

authors： Augustin AJ,Diehm C,Grieger F,Bentz J

更新日期：2013-07-01 00:00:00

abstract：INTRODUCTION:Regorafenib (BAY 73-4506) is a novel, orally active, diphenylurea multikinase inhibitor of VEGFR1-3, c-KIT, TIE-2, PDGFR-β, FGFR-1, RET, RAF-1, BRAF and p38 MAP kinase. AREAS COVERED:This review covers the preclinical development of regorafenib as well as the pivotal Phase I studies. The safety profile of...

journal_title：Expert opinion on investigational drugs

authors： Strumberg D,Schultheis B

更新日期：2012-06-01 00:00:00

abstract：:Atherothrombosis, or thrombus formation, at the site of a disrupted atherosclerotic plaque is the common pathophysiology related to myocardial infarction, ischaemic stroke and peripheral arterial disease. A growing body of evidence demonstrates an important role for vascular inflammation in the pathophysiology of athe...

journal_title：Expert opinion on investigational drugs

authors： Herbert JM

更新日期：2004-05-01 00:00:00

abstract：:Since the introduction of the first through the skin (TTS) therapeutic in 1980, a total of 34 TTS products have been marketed and numerous drugs have been tested by more than 50 commercial organisations for their suitability for TTS delivery. Most of the agents which have been tested have had low molecular weights, du...

journal_title：Expert opinion on investigational drugs

authors： Cevc G

更新日期：1997-12-01 00:00:00

abstract：INTRODUCTION:Obesity is a major health threat in the Western world because of its high incidence and prevalence, and its association with metabolic and cardiovascular disease as well as cancer. The reduction of food intake in obese patients can be achieved only transiently (generally for no longer than 6 months), in th...

journal_title：Expert opinion on investigational drugs

authors： Folli F,Guardado Mendoza R

更新日期：2011-12-01 00:00:00

abstract：BACKGROUND:Potent new drugs against multidrug-resistant Gram-negative bacteria, namely Pseudomonas aeruginosa and Acinetobacter spp. and pan-drug-resistant Klebsiella pneumoniae, which constitute an increasing medical threat, are almost absent from the future pharmaceutical pipeline. OBJECTIVE:This drug evaluation foc...

journal_title：Expert opinion on investigational drugs

authors： Poulakou G,Giamarellou H

更新日期：2008-05-01 00:00:00

abstract：:Biologically-based skin substitutes have developed as commercial products over the last 5 years. The first generation includes the collagen-based synthetic device, Integra, and Alloderm, which is based on devitalised and cross-linked human dermis. These are used as dermal replacements for third degree burns. Within th...

journal_title：Expert opinion on investigational drugs

authors： Mansbridge J

更新日期：1998-05-01 00:00:00

abstract：:The tremendous increase in the global prevalence of Type 2 diabetes (T2D) and its conglomeration of metabolic disorders has dramatically intensified the search for innovative therapies to fight this emerging epidemic. Over the last decade, the family of nuclear receptors, especially the peroxisome proliferator-activat...

journal_title：Expert opinion on investigational drugs

authors： Savkur RS,Miller AR

更新日期：2006-07-01 00:00:00

abstract：:Interstitial cystitis (IC) is a painful, sterile, disorder of the urinary bladder characterised by urgency, frequency, nocturia and pain. IC occurs primarily in women but also in men with recent findings indicating that chronic, abacterial prostatitis may be a variant of this condition. The prevalence of IC has ranged...

journal_title：Expert opinion on investigational drugs

authors： Theoharides TC,Sant GR

更新日期：2001-03-01 00:00:00

abstract：INTRODUCTION:Peripheral arterial disease (PAD) is a manifestation, and marker of severity, of a generalized atherosclerotic process. Antiplatelet therapy is recommended to prevent cardiovascular events but much of the evidence to support this is drawn from studies on older drugs. AREAS COVERED:In this review, the auth...

journal_title：Expert opinion on investigational drugs

authors： Chong AY,So DY

更新日期：2014-12-01 00:00:00

abstract：:Argatroban, a synthetic peptidomimetic antithrombin agent, is the first clinical anticoagulant solely to target thrombin. For some time, this drug has been used in Japan for the management of thromboembolic disorders. Recently, it has been approved in Japan for use in thrombotic and ischaemic stroke. Despite a large n...

journal_title：Expert opinion on investigational drugs

authors： Jeske W,Walenga JM,Lewis BE,Fareed J

更新日期：1999-05-01 00:00:00

abstract：:Zolmitriptan is a new oral acute treatment for migraine. It is a selective and potent agonist at the serotonin (5-HT)(1B/1D) receptor and was developed to improve on the oral bioavailability, tissue selectivity and CNS penetration of earlier compounds. Animal studies confirmed that these objectives had been attained. ...

journal_title：Expert opinion on investigational drugs

authors： Rolan PE,Martin GR

更新日期：1998-04-01 00:00:00

abstract：:Major depressive disorder (MDD) affects

journal_title：Expert opinion on investigational drugs

authors： Khan A

更新日期：2009-11-01 00:00:00

abstract：:Recombinant toxins constitute a new modality for the treatment of cancer, since they target cells displaying specific surface-receptors or antigens. They are fusion proteins, which contain toxin and ligand regions, and are produced in Escherichia coli. The ligand may be a growth factor or a fragment of an antibody, an...

journal_title：Expert opinion on investigational drugs

authors： Kreitman RJ

更新日期：1998-09-01 00:00:00

abstract：INTRODUCTION:Duchenne muscular dystrophy (DMD) is an X-linked recessive disorder caused by mutations in the dystrophin (DMD) gene. Most patients die from respiratory failure or cardiomyopathy. There are significant unmet needs for treatments for DMD as the standard of care is principally limited to symptom relief throu...

journal_title：Expert opinion on investigational drugs

authors： Sheikh O,Yokota T

更新日期：2021-01-06 00:00:00

abstract：INTRODUCTION:Axial spondyloarthritis (AxS pA) is a chronic inflammatory disease for which, until recently, there were no valid therapeutic alternatives to TNF-α blocking agents. This unmet clinical need led to explore several therapeutic targets, from proinflammatory cytokines to intracellular signaling systems. The re...

journal_title：Expert opinion on investigational drugs

authors： Clavel G,Boissier MC,Sigaux J,Semerano L

更新日期：2017-07-01 00:00:00

abstract：:Recent landmark studies using hydroxy-methyl-glutaryl-Co-enzyme A reductase inhibitors (HMG-CoA reductase inhibitors or statins), specifically, pravastatin and simvastatin, have led to dramatic changes in medical practice. These clinical trials have demonstrated that clinicians can impact coronary morbidity and mortal...

journal_title：Expert opinion on investigational drugs

authors： Mellies M,McGovern M

更新日期：1997-01-01 00:00:00

abstract：INTRODUCTION:Sepsis with Bacillus anthracis infection has a very high mortality rate despite appropriate antibiotic and supportive therapies. Over the past 15 years, recent outbreaks in the US and in Europe, coupled with anthrax's bioterrorism weapon potential, have stimulated efforts to develop adjunctive therapies to...

journal_title：Expert opinion on investigational drugs

authors： Ohanjanian L,Remy KE,Li Y,Cui X,Eichacker PQ

更新日期：2015-01-01 00:00:00

abstract：INTRODUCTION:Idiopathic pulmonary fibrosis (IPF) is an age-associated, progressive, and irreversible fatal interstitial lung disease. Although many drugs have failed in clinical trials, these failures improved the understanding of the pathogenesis of IPF. Currently, there are two drugs approved for IPF that slow the pr...

journal_title：Expert opinion on investigational drugs

authors： Sato S,Yanagihara T,Kolb MRJ

更新日期：2019-01-01 00:00:00

abstract：:Considerable progress has been made with tyrosine kinase inhibitors. After long and sustained efforts, several tyrosine kinase inhibitors with convincing in vivo experimental antitumour properties such as CP-358,774, ZD 1839, CEP-751 are entering Phase I clinical trials. Significant in vivo experimental antitumour act...

journal_title：Expert opinion on investigational drugs

authors： Lavelle F

更新日期：1997-06-01 00:00:00

abstract：INTRODUCTION:Heat shock proteins (Hsps) are part of a complex network of chaperone proteins that are critically involved in the conformational maturation of intracellular proteins and regulate their degradation via the proteasome system Hsps (especially Hsp70 and Hsp90) are upregulated in many cancers and are potential...

journal_title：Expert opinion on investigational drugs

authors： Subramaniam DS,Warner EA,Giaccone G

更新日期：2017-01-01 00:00:00

abstract：:Helicobacter pylori infection causes peptic ulcer disease and must be regarded as a serious infectious disease. Over the past two decades treatment of the infection has been a controversial issue. Treatment is purely empirical and based on combinations of two, three or four existing drugs. Antimicrobial resistance is ...

journal_title：Expert opinion on investigational drugs

authors： de Boer WA

更新日期：2001-08-01 00:00:00

abstract：INTRODUCTION:Tetomilast is a novel thiazole phosphodiesterase-4 (PDE-4) inhibitor, which may prove useful in both the treatment of inflammatory bowel disease (IBD) and chronic obstructive pulmonary disease (COPD). Here, the authors review the pharmacology of the drug, and offer critical review of the available data for...

journal_title：Expert opinion on investigational drugs

authors： Bickston SJ,Snider KR,Kappus MR

更新日期：2012-12-01 00:00:00

abstract：:Phytoestrogens, such as the soya isoflavones genistein and daidzein, are currently being extensively investigated through both molecular, preclinical and clinical studies to determine their potential health benefits. Phytoestrogens may protect against chronic diseases such as hormone-dependent cancer (e.g., breast and...

journal_title：Expert opinion on investigational drugs

authors： Wiseman H

更新日期：2000-08-01 00:00:00

abstract：:It is now widely accepted that the renin-angiotensin system (RAS) not only contributes to pathological mechanisms involved, e.g. in hypertension or hypertensive and diabetic end-organ damage, but also harbors a "protective arm" represented mainly by two receptors, the AT2 (angiotensin type 2) receptor and the Mas rece...

journal_title：Expert opinion on investigational drugs

authors： Steckelings UM,Unger T

更新日期：2012-06-01 00:00:00

abstract：INTRODUCTION:IL-6 is a key cytokine in the pathogenesis of rheumatoid arthritis (RA). The clinical efficacy of tocilizumab (TCZ), a humanized anti-IL6-receptor mAb, confirmed the value of IL-6 blockade in this disease. A number of new anti-IL-6 biologics are currently in Phase I - III of clinical development for RA. A...

journal_title：Expert opinion on investigational drugs

authors： Semerano L,Thiolat A,Minichiello E,Clavel G,Bessis N,Boissier MC

更新日期：2014-07-01 00:00:00

abstract：BACKGROUND:Dexamethasone cipecilate is a corticosteroid nasal spray whose local efficacy durability has been improved by introduction of a liposoluble functional group to its chemical structure. This study was conducted to evaluate the efficacy of once-daily treatment with this drug in patients with perennial allergic ...

journal_title：Expert opinion on investigational drugs

authors： Gotoh M,Okubo K,Okuda M,Hamada C

更新日期：2010-12-01 00:00:00

abstract：INTRODUCTION:Epithelial ovarian cancer (EOC) is the fourth commonest cause of female cancer death in the developed world. Although progress in treatment has improved survival, ∼ 80% of patients with advanced EOC will experience a recurrence and eventually will become resistant to chemotherapy. The aim of treatment for ...

journal_title：Expert opinion on investigational drugs

authors： Marchetti C,Ledermann JA,Benedetti Panici P

更新日期：2015-01-01 00:00:00